Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collabor...

Descripción completa

Detalles Bibliográficos
Autores principales: Funnell, S. G. P., Dowling, W. E., Muñoz-Fontela, C., Gsell, P.-S., Ingber, D. E., Hamilton, G. A., Delang, L., Rocha-Pereira, J., Kaptein, S., Dallmeier, K. H., Neyts, J., Rosenke, K., de Wit, E., Feldmann, H., Maisonnasse, P., Le Grand, R., Frieman, M. B., Coleman, C. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450055/
https://www.ncbi.nlm.nih.gov/pubmed/32848158
http://dx.doi.org/10.1038/s41467-020-17907-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450055/
https://www.ncbi.nlm.nih.gov/pubmed/32848158
http://dx.doi.org/10.1038/s41467-020-17907-w

Ejemplares similares